Pharmaceutical sciences

Cannabis Edibles Market Projected to Quadruple in U.S. and Canada to $4.1 Billion

Retrieved on: 
Wednesday, July 31, 2019
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Edible, Dispensary, Health sciences, Health, Pharmaceutical sciences

Another report from BDS Analytics added that the place where these increased edibles will be sold will be/has been in dispensaries.

Key Points: 
  • Another report from BDS Analytics added that the place where these increased edibles will be sold will be/has been in dispensaries.
  • They projected that overall, CBD sales are expected to surge to $20 billion by 2024; up substantially from the $1.9 billion in 2018.
  • Retail tracking and forecast models include products sold through licensed dispensaries, pharmaceuticals and in general market retail, encompassing the full CBD market.
  • Created in hand-crafted small batches, the edibles are made with Cypress Extract of cannabis paired with unique flavor blends.

Canntab provides corporate update

Retrieved on: 
Wednesday, July 31, 2019
Pharmacology, Dosage forms, Health sciences, Pharmaceutical industry, Pharmaceutical sciences, Capsule, Tablet

Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status.

Key Points: 
  • Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status.
  • TORONTO, July 31, 2019 /PRNewswire/ - Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to provide an update on a number of significant developments, as well as a clear outline of what to expect in the coming months as edible products become legalized.
  • Oil-filled gel capsules will represent the first stream of revenue for Canntab before we are able to launch our flagship hard tablet products in October, pending Health Canada approval.
  • In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace.

European CNS Specialist Neuraxpharm Launches First Products in the United Kingdom

Retrieved on: 
Wednesday, July 31, 2019
Health sciences, Pharmaceutical industry, Pharmacology, Pharmacy, Health, Pharmaceutical sciences

LANGENFELD, Germany, July 31, 2019 /PRNewswire/ -- Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launchof its first products in the United Kingdom.

Key Points: 
  • LANGENFELD, Germany, July 31, 2019 /PRNewswire/ -- Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launchof its first products in the United Kingdom.
  • Neuraxpharm also announces the appointment of new General Manager Craig Bowen, who will run Neuraxpharm UK Ltd ., based in Reading (Berkshire, UK).
  • Neuraxpharm strategy is to build on its position as a CNS specialist in Europe offering consumer healthcare products, standard generics and added value medicines.
  • With its focus on CNS, Neuraxpharm develops and commercializes value added medicines, standard generics and consumer healthcare products, e.g.

European CNS Specialist Neuraxpharm Launches First Products in the United Kingdom

Retrieved on: 
Wednesday, July 31, 2019
Health sciences, Pharmaceutical industry, Pharmacology, Pharmacy, Health, Pharmaceutical sciences

LANGENFELD, Germany, July 31, 2019 /PRNewswire/ -- Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launchof its first products in the United Kingdom.

Key Points: 
  • LANGENFELD, Germany, July 31, 2019 /PRNewswire/ -- Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launchof its first products in the United Kingdom.
  • Neuraxpharm also announces the appointment of new General Manager Craig Bowen, who will run Neuraxpharm UK Ltd ., based in Reading (Berkshire, UK).
  • Neuraxpharm strategy is to build on its position as a CNS specialist in Europe offering consumer healthcare products, standard generics and added value medicines.
  • With its focus on CNS, Neuraxpharm develops and commercializes value added medicines, standard generics and consumer healthcare products, e.g.

4Front Provides Update on Mission Dispensaries Milestones

Retrieved on: 
Tuesday, July 30, 2019
Cannabis dispensaries in the United States, Cannabis in the United States, Dispensary, Backus, Cannabis, Health, Pharmaceutical sciences

PHOENIX, July 30, 2019 /PRNewswire/ --4Front Holdings LLC ("4Front") is pleased to provide an operational update on Mission, its branded network of cannabis dispensaries.

Key Points: 
  • PHOENIX, July 30, 2019 /PRNewswire/ --4Front Holdings LLC ("4Front") is pleased to provide an operational update on Mission, its branded network of cannabis dispensaries.
  • By the end of the year, Mission is expected to own or operate 11 dispensaries in six states: Arizona, Illinois, Massachusetts, Maryland, Michigan and Pennsylvania.
  • "Mission President Glenn Backus and the rest of the Mission team have been steadfast in their determination to get our new locations stood up and operational.
  • "Our vision for Mission is to run the best dispensaries for inspiring cannabis customers," said Glenn Backus, President of Mission.

Pharmaceutical Contract Development and Manufacturing Industry Worth $126.6 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, July 29, 2019
Health, Pharmaceutical sciences, Big Pharma, Pharmaceutical industry, Pharma

On the basis of the end user, the big pharma segment is expected to account for the largest share of the Pharmaceutical Contract Development and Manufacturing Market

Key Points: 
  • On the basis of the end user, the big pharma segment is expected to account for the largest share of the Pharmaceutical Contract Development and Manufacturing Market
    The big pharma end-user segment is estimated to account for the largest market share in 2019.
  • Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.
  • Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM".
  • MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments.

Pharmaceutical Contract Development and Manufacturing Industry Worth $126.6 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, July 29, 2019
Health, Pharmaceutical sciences, Big Pharma, Pharmaceutical industry, Pharma

On the basis of the end user, the big pharma segment is expected to account for the largest share of the Pharmaceutical Contract Development and Manufacturing Market

Key Points: 
  • On the basis of the end user, the big pharma segment is expected to account for the largest share of the Pharmaceutical Contract Development and Manufacturing Market
    The big pharma end-user segment is estimated to account for the largest market share in 2019.
  • Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.
  • Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM".
  • MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments.

Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation

Retrieved on: 
Tuesday, July 23, 2019
Health sciences, Health, Pharmaceutical sciences, Habits, RTT, Medicinal chemistry, Pharmacokinetics, Toxicokinetics, Toxicology, Pharmacology, Smoking, Nicotine replacement therapy

"Smoking continues to be the leading cause of preventable death around the world, and new treatment options have the potential to complement existing evidence-based cessation strategies."

Key Points: 
  • "Smoking continues to be the leading cause of preventable death around the world, and new treatment options have the potential to complement existing evidence-based cessation strategies."
  • These studies included genotoxicity testing, safety pharmacology, cardiac conduction studies, pharmacokinetics, toxicokinetics, and the required toxicology studies in two species.
  • In total, the NIH has committed approximately $6 million dollars to the development of cytisinicline.
  • Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

Comprehensive Reconciliation Support by a PSAO Partner Means More Money for Pharmacies, More Time for Customers

Retrieved on: 
Tuesday, July 16, 2019
Insurance, Professional services, Practice Management, Pharmaceutical, General Health, Health, Other Professional Services, Health sciences, Pharmacies, Health, Pharmaceutical sciences, Medicinal chemistry, Independent pharmacy, Reconciliation

This is where a Pharmacy Services Administrative Organization (PSAO) can help by providing reconciliation support that allows pharmacies to focus on customer service.

Key Points: 
  • This is where a Pharmacy Services Administrative Organization (PSAO) can help by providing reconciliation support that allows pharmacies to focus on customer service.
  • Pharmacy First, one of the nations leading PSAOs, recently published The Value of Comprehensive Claims Reconciliation , a white paper that explores how reconciliation services from a high-functioning PSAO can save pharmacy owners valuable time and money.
  • In The Value of Comprehensive Claims Reconciliation , Otte examines a PSAOs ability to provide comprehensive, end-to-end support for all claims reconciliation and recoupment by:
    Ottes advice to independent pharmacy owners: Not all PSAOs offer the same level of reconciliation service.
  • Look for a PSAO partner that offers end-to-end reconciliation support on all claims, so you can maximize profits, minimize losses and give your customers the time they deserve.

RXinsider Introduces the Pharmacy Market BUZZ

Retrieved on: 
Monday, July 15, 2019
Health, Pharmaceutical sciences, Pharmacies, Independent pharmacy

WEST WARWICK, R.I., July 15, 2019 /PRNewswire-PRWeb/ -- RXinsider launches a new daily news feed, the Pharmacy Market BUZZ, to educate independent pharmacy owners, health system directors of pharmacy, and retail pharmacy chain executives on the latest market news focused on the "business of pharmacy".

Key Points: 
  • WEST WARWICK, R.I., July 15, 2019 /PRNewswire-PRWeb/ -- RXinsider launches a new daily news feed, the Pharmacy Market BUZZ, to educate independent pharmacy owners, health system directors of pharmacy, and retail pharmacy chain executives on the latest market news focused on the "business of pharmacy".
  • The Pharmacy Market BUZZ enables followers to stay current on issues and products that impact both patient care and the bottom line of their pharmacy, including: